ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC
20 Feb 2020
byJairia Dela Cruz
Among patients with ulcerative colitis (UC), vedolizumab serum concentrations in the fifth week after treatment initiation appear to have been higher in those who do vs do not show response in the sixth week, according to interim data from ENTERPRET study presented at the 2020 Crohn’s and Colitis Congress (CCC).